

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 68

April 13, 2026

ISSUE No.  
**1752**

### IN THIS ISSUE

**In Brief: Ranitidine Returns** ..... p 63

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter®

## on Drugs and Therapeutics

Volume 68 (Issue 1752)

April 13, 2026

Take CME Exams

### IN BRIEF

#### Ranitidine Returns

The FDA has approved a new tablet formulation of the H<sub>2</sub>-receptor antagonist (H<sub>2</sub>RA) ranitidine from one manufacturer (VKT Pharma/Rising Pharma). It is only available by prescription. In 2020, the FDA requested that all formulations of ranitidine be withdrawn from the market because unacceptable levels of the nitrosamine compound *N*-nitrosodimethylamine (NDMA), a potentially carcinogenic contaminant, had been detected in ranitidine samples.

**NDMA** – NDMA can be found in drinking water (as a byproduct of water disinfection) and in some processed foods. It has been found in many drugs, including nizatidine, which is structurally related to ranitidine. High levels of NDMA have been shown to induce tumors in multiple organs in animals; it is classified as a probable human carcinogen.

FDA testing found that NDMA levels in the original ranitidine formulations increased over time and when the drug was stored at high temperatures. Approval of the reformulated tablets was based on changes in the manufacturing process that improve the stability of the drug, minimizing formation of NDMA during its shelf life.

**Table 1. Storage and Handling of Ranitidine Tablets**

- ▶ Dispense and keep tablets in the original bottle with the desiccant.
- ▶ If more than one bottle is dispensed, open only one bottle at a time. Store additional bottles without opening until needed for dosing.
- ▶ At the time of dosing, remove one tablet from the bottle. Immediately close the bottle, secure the cap, and keep the bottle tightly closed to protect from moisture.
- ▶ Discard unused tablets 3 months (90 days) after first opening the bottle or by the expiration date on the bottle, whichever is sooner.

**AVAILABILITY** – Prior to removal, ranitidine was available over the counter (OTC) and by prescription (*Zantac*, and generics).<sup>1</sup> The active ingredient in OTC *Zantac 360* is now the H<sub>2</sub>RA famotidine (see Table 2).

The new formulation is available by prescription in bottles of 30 tablets containing either 150 mg or 300 mg of ranitidine. The bottles should be stored at 15-30°C (59-86°F) in a dry place and protected from light. The updated label states that the tablets must be dispensed in the original container. The label also includes storage and handling instructions for patients (see Table 1).

**Table 2. H<sub>2</sub>-Receptor Antagonists**

| Drug   | Oral Formulations                               | Usual Adult Dosage | Cost <sup>1</sup>  |
|--|---|--------------------|--------------------|
| Cimetidine – generic                               | 200, 300, 400, 800 mg tabs;<br>300 mg/5 mL soln | 200-400 mg bid     | \$18.10            |
| <i>Tagamet HB</i> (OTC) <sup>2</sup> (Medtech)     | 200 mg tabs                                     |                    | 18.00              |
| Famotidine – generic                               | 20, 40 mg tabs; 40 mg/5 mL susp                 | 20-40 mg bid       | 3.20               |
| <i>Pepcid AC</i> (OTC) <sup>2</sup> (J&J Consumer) | 10, 20 mg tabs                                  |                    | 18.20 <sup>3</sup> |
| <i>Zantac 360</i> (OTC) <sup>2</sup> (Chattem)     | 20 mg tabs                                      |                    | 12.50 <sup>3</sup> |
| Nizatidine – generic                               | 150, 300 mg caps; 15 mg/mL soln                 | 150 mg bid         | 50.00              |
| Ranitidine – generic<br>(VKT Pharma/Rising Pharma) | 150, 300 mg tabs                                | 150 mg bid         | 398.10             |

OTC = over the counter; soln = solution; susp = suspension

1. Approximate WAC for 30 days' treatment with the lowest usual adult dosage. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy.

2. Also available generically.

3. Approximate WAC for fifty 20-mg tablets.

**FDA GUIDANCE** – The FDA recently issued guidance on acceptable intake (AI) limits for NDMA and some other nitrosamine impurities in drugs. The AI represents the level at or below which the impurity would not be considered a safety concern.<sup>2</sup> The updated ranitidine label states that the formulation meets FDA-approved specifications for nitrosamine impurities. ■

1. Drugs for GERD and peptic ulcer disease. *Med Lett Drugs Ther* 2022; 64:49.
2. FDA. CDER nitrosamine impurity acceptable intake limits. March 19, 2026. Available at: <https://bit.ly/4qpMFjQ>. Accessed March 26, 2026.

**PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **EDITOR IN CHIEF EMERITUS:** Mark Abramowicz, M.D.; **VICE PRESIDENT, ADMINISTRATION:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., B.C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli  
**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

**Address:**  
The Medical Letter, Inc.  
2 Madison Ave, Ste 211  
Larchmont, NY 10538  
[www.medicalletter.org](http://www.medicalletter.org)

**Customer Service:**  
Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

**Permissions:**  
To reproduce any portion of this issue,  
please e-mail your request to:  
[permissions@medicalletter.org](mailto:permissions@medicalletter.org)

**Subscriptions (US):**  
1 year – \$179; \$65 per year  
for students, interns, residents,  
and fellows in the US and Canada.  
Reprints – \$45 per issue or article

**Site License Inquiries:**  
E-mail: [SubQuote@medicalletter.org](mailto:SubQuote@medicalletter.org)  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.